Know Labs Inc

Know Labs, Inc. engages in the development, marketing, and sale of a photonics technology. It offers its product under the ChromaID brand. The firm operates through the following segments: The Development of Bio-RFID and ChromaID Technology, Particle, Inc. Technology, and AI Sales of NFT Products. Know Labs was founded by Ronald Peter Erickson on October 8, 1998 and is headquartered in Seattle, WA.

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Know Labs Inc reports improved Q1 performance amidst leadership changes

Know Labs Inc's Q1 2023 earnings call highlighted improved financial performance, progress on Bio-RFID technology, and reassurance of continued momentum despite leadership changes.
The company's strengths lie in innovation, strategic partnerships, and a focus on glucose monitoring, while facing challenges in regulatory approvals and leadership transitions.
Opportunities for Know Labs include diversifying their analyte identification capabilities, leveraging manufacturing partnerships, and capitalizing on the demand for healthcare innovation.

Know Labs reports Q3 loss but shows promise in innovation

Know Labs showcased progress in innovation and research, with a focus on reducing the burn rate. However, challenges include the net loss in Q3 2023 and the need to address market cap concerns. Opportunities exist in leveraging strategic partnerships and potential FDA approvals for future growth.

Know Labs Inc reports Q3 achievements, navigates financial challenges

Know Labs Inc demonstrated strong performance in Q3 2023, with notable achievements in technology development, clinical testing, and IP portfolio expansion.
While facing financial challenges and regulatory hurdles, the company's strategic focus on innovation and cost management positions it for future growth and success.
By leveraging opportunities in data collection, regulatory strategy, and fundraising, Know Labs Inc aims to drive innovation and achieve key milestones in the coming quarters.

Know Labs reports improved FY 2023 performance and unveils Generation 2 device

Know Labs Inc showcased strong financial and operational performance in FY 2023, underpinned by strategic advancements and prudent financial management.
While challenges exist in product development and cost management, the company's focus on innovation and market validation bodes well for future growth.
With a positive outlook for FY 2024 and a clear roadmap for product development, Know Labs is poised to capitalize on market opportunities and drive value for stakeholders.

Know Labs advances noninvasive glucose monitoring with strong IP portfolio

Know Labs Inc (KNW) demonstrated progress in technology development, financial management, and strategic planning during Q1 2024.
While facing challenges in burn rate management and market competition, the company's strong IP portfolio and clinical focus present growth opportunities.
Overall, Know Labs shows promise in innovation, financial stability, and market expansion, positioning itself for future success in the medical device sector.

Know Labs reports strong Q2 performance with promising product launches

Know Labs Inc demonstrated strong performance in Q2 2024, marked by financial improvements, successful product launches, and promising clinical trial results.
The company's strengths lie in innovation, intellectual property, and operational efficiency, positioning them well for future growth and market success.
Challenges around financing, regulatory approvals, and market competition require strategic focus and proactive management to capitalize on growth opportunities.
Opportunities in international expansion, product development, partnerships, and regulatory compliance offer avenues for Know Labs to drive revenue and market presence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced interim results from its most recent clinical research study. The study assessed the accuracy of Know Labs' proprietary radiofrequency (RF) dielectric sensor in non-invasively measuring blood glucose in participants with prediabetes and Type 2 diabetes using venous blood as a comparative reference – resulting in an overall Mean Absolute Relative Di.

Know Labs' Non-Invasive Glucose Monitor Achieves 11.1% MARD in Latest Clinical Research Study

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has entered into a funding agreement for an investment of up to $12 million, of which it has executed a $4 million close (the “Funding Agreement”) with Lind Global Fund II LP, an investment entity managed by The Lind Partners, a New York-based institutional fund manager (together, “Lind”). Ron Erickson, Chief Executive Officer and Chairman at Kn.

Know Labs Secures U.S. $12 Million Funding for Company's Further Execution on Its Clinical Research and Development Initiatives

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the KnowU™, its wearable non-invasive continuous glucose monitor (CGM). The Company announced its first prototype in June 2023. The KnowU is the result of an accelerated development process over the last eight months. The KnowU incorporates the sensor that the Company plans to submit to the FDA for clearance. This proprietary sensor has been tested.

Know Labs Announces the KnowU™, its Wearable Non-Invasive Continuous Glucose Monitor

Know Labs, Inc. (KNW) Q1 2024 Earnings Call Transcript

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the first quarter ended December 31, 2023. Financial Highlights: In Q1 FY 2024, Know Labs reported a net loss of $3.45 million dollars, compared to a net loss of $3.82 million dollars in Q1 FY 2023, a reduction in net loss of 9.8%. This translates to Earnings Per Share of a loss of $0.04, better than the prior year quarter Earn.

Know Labs, Inc. Reports First Quarter FY2024 Results

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it will host a webcast to review business updates and results for its first quarter of the fiscal year 2024 ended on December 31, 2023, on February 14, 2024, beginning at 1:30 pm PT. Media and investors may access the live audio webcast at www.knowlabs.co/investors, beginning at 1:15 pm PT. Questions to the Company's management team can be submitte.

Know Labs, Inc. to Host Review of First Quarter Fiscal Year 2024 Results on February 14, 2024

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the company will be exhibiting at the International Fair of New Technologies in Diabetes at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Florence, Italy on March 6-9, 2024. The Company will share updates on the latest developments of its non-invasive blood glucose monitor and present results fro.

Know Labs to Exhibit at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

Know Labs, Inc. (KNW) Q4 2023 Earnings Call Transcript

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the fourth quarter and fiscal year ended September 30, 2023. Financial Highlights: Know Labs reported a net loss of $15.29 million dollars in FY2023, compared to a net loss of $20.07 million dollars in FY2022, a reduction in net loss of 23.8%. This translates to Earnings Per Share of a loss of $0.41, better than FY2022 Earnings.

Know Labs, Inc. Reports Fourth Quarter and Fiscal Year 2023 Results

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the appointment of four new members to the Company's Medical and Scientific Advisory Board. The new additions to the Advisory Board are Jeff Hitchcock, Karmeen Kulkarni, Dr. Meng Tan and Dr. Satish Garg. They bring to the board extensive experience in clinical diabetes management, including the advancement of new technologies and innovation in medi.

Know Labs Expands Medical and Scientific Advisory Board

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it will host a webcast to review business updates and results for its fiscal year ended on September 30, 2023, on December 19, 2023, beginning at 1:30 pm PT. Media and investors may access the live audio webcast at www.knowlabs.co/investors, beginning at 1:15 pm PT. Questions to the Company's management team can be submitted through the webcast por.

Know Labs, Inc. to Host Review of Fiscal Year 2023 Results on December 19, 2023

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the appointment of three new members to the Company's Board of Directors. These appointments increase the number of Directors to seven. Each new Director brings to the board extensive sector-relevant experience with deep knowledge of the science and the marketplace that is the focus of Know Labs. The new appointees are John Cronin, Larry Ellingson.

Know Labs Expands Board of Directors

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, will present at the third annual Bernstein CGM Disruptors Conference on Thursday, November 2, 2023. Presenters and institutional investors from across the globe will gather virtually to discuss the latest developments in continuous glucose monitoring (CGM) technology. Pete Conley, Chief Financial Officer, and Senior Vice President of Intellectual Property (IP) at.

Know Labs Presents at Third Annual Bernstein CGM Disruptors Conference, Details Significant Progress During the Past Year

Know Labs (NYSEMKT: KNW ) stock is falling on Wednesday as the company biosensor technologies company launches a public share offering. This public offering has Know Labs selling 28 million shares of KNW stock at a price of 25 cents per share.

Why Is Know Labs (KNW) Stock Down 37% Today?

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW) (the “Company”), an emerging developer of non-invasive medical diagnostic technology, today announced the pricing of a firm commitment underwritten public offering of 28,000,000 shares of its common stock at a public offering price of $0.25 per share (the "Offering"). The aggregate gross proceeds from the Offering are expected to total $7 million before deducting the underwriting discounts and commissions and estimated Offering expe.

Know Labs, Inc. Announces Pricing of $7 Million Public Offering of Common Stock

Know Labs, Inc. (NYSE:KNW ) Q3 2023 Results Conference Call August 14, 2023 4:30 PM ET Company Participants Jordyn Hujar - Chief of Staff Ron Erickson - Chairman and Chief Executive Officer Pete Conley - Senior Vice President and Chief Financial Officer Operator Greetings. Welcome to the Know Labs Fiscal Year 2023 Third Quarter Earnings Conference Call.

Know Labs, Inc. (KNW) Q3 2023 Earnings Call Transcript

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the third quarter ended June 30, 2023. Financial Highlights: Know Labs reported a net loss of $3.59 million dollars in the third quarter of 2023, compared to a net loss of $3.03 million dollars in the year-ago period, which translates to Earnings Per Share of a loss of $0.07, unchanged from the year ago period of a loss of $0.0.

Know Labs, Inc. Reports Third Quarter FY2023 Results

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it will host a webcast to review business updates and results for its third quarter of the fiscal year 2023 ended on June 30, 2023, on August 14, 2023, beginning at 1:30 pm PT. Media and investors may access the live audio webcast at www.knowlabs.co/investors, beginning at 1:15 pm PT. Questions to the Company's management team can be submitted thro.

Know Labs, Inc. to Host Review of Third Quarter Fiscal Year 2023 Results on August 14, 2023

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW) today announced results from a new study titled, “Novel data preprocessing techniques in an expanded dataset improve machine learning model accuracy for a non-invasive blood glucose monitor.” The study demonstrates that continued algorithm refinement and more high-quality data improved the accuracy of Know Labs' proprietary Bio-RFID sensor technology, resulting in an overall Mean Absolute Relative Difference (MARD) of 11.3%. As with.

Know Labs Demonstrates Improved Accuracy of Machine Learning Model for Non-Invasive Glucose Monitor

SEATTLE--(BUSINESS WIRE)--Know Labs (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, revealed the next stage in the development of its proprietary Bio-RFID™ technology – the Generation (Gen) 1 Device. Gen 1 incorporates Know Labs' Bio-RFID sensor – which has been proven as technically feasible and stable in delivering repeatable results in measuring blood glucose when used in a lab environment – in a portable device. Currently, there are no medical-grad.

Know Labs Completes Build of Portable Generation 1 Prototype for Non-Invasive Glucose Monitoring

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW) today announced the results of a new study titled, “Algorithm Refinement in the Non-Invasive Detection of Blood Glucose Using Know Labs' Bio-RFID Technology.” The study demonstrates that algorithm optimization using a light gradient-boosting machine (lightGBM) machine learning model improved the accuracy of Know Labs' Bio-RFID™ sensor technology at quantifying blood glucose, demonstrating an overall Mean Absolute Relative Difference.

Know Labs' Non-Invasive Glucose Monitoring Technology Shows Improved Accuracy

Phoenix, Arizona--(Newsfile Corp. - May 25, 2023) - The Stock Day Podcast welcomed Know Labs, Inc. (NYSE American: KNW) ("the Company"), an emerging developer of non-invasive medical diagnostic technology. The Company refers to its novel technology as Bio-RFID™ which directs electromagnetic energy in the form of radio waves through organic or inorganic materials to capture a unique molecular signature.

Know Labs, Inc. Discusses Significant Growth of Its IP Portfolio and 2023 Goals with The Stock Day Podcast

SEATTLE--(BUSINESS WIRE)--Know Labs (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced that Pete Conley, its Chief Financial Officer and Senior Vice President of Intellectual Property (IP), will speak at the upcoming 2023 Intellectual Property Business Congress (IPBC) Global event in June – the world's largest gathering of leaders and decision-makers operating in the global IP market. Mr. Conley is participating as a panelist in a discussi.

Know Labs Joins IPBC Global 2023 to Discuss the Importance of Strategic IP Development in Maximizing Shareholder Value

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the publication of its first peer-reviewed study in Sensors Journal. The manuscript titled, Detecting Unique Analyte-Specific Radio Frequency Spectral Responses in Liquid Solutions—Implications for Non-Invasive Physiologic Monitoring, describes the proof-of-principle study of Know Labs' Bio-RFID technology that quantified different analytes in vitr.

Know Labs Furthers External Validation of Bio-RFID™ Technology with Study Published in Sensors Journal

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the second quarter ended March 31, 2023. Financial Highlights: Know Labs reported a net loss of $4.93 million dollars in the second quarter of 2023, compared to a net loss of $6.14 million dollars in the year-ago period, which translates to Earnings Per Share of a loss of $0.10, an improvement over the year ago period of a loss.

News for Know Labs Inc Stock (KNW)